Athens, GR, September 2nd, 2009 — Biovista Inc. is pleased to announce its sponsoring of the international 2009 Notch Meeting to be held in Athens, Greece, from September 27th to October 1st, 2009. The Notch Meeting is a biennial event on general Notch research that aims to reflect the diversity of Notch research and bring together researchers … Read More
News
Biovista Inc. announces positive efficacy results in a pre-clinical trial of its BVA-601 drug for Epilepsy
CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ — Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant … Read More
Biovista’s Unusual Brand of In Silico Drug Discovery
Interview of Aris Persidis to Bio-IT World’s John Russell May 14, 2009 | It’s interesting what crops up in company executive profiles. Aris Persidis is an accomplished bio-entrepreneur and the co-founder of Biovista along with his brother Andreas Persidis. Aris’s company profile includes the usual details—Cellzome co-founder, Ph.D. from Cambridge University in biochemistry, etc.—but the very last … Read More
The future of drug repositioning
Andreas Persidis of Biovista talks to NGP about the transformational potential of drug repositioning. NGP. Drug repositioning seems to be attracting increasing interest in the pharmaceutical world. Is there a real need for it? Andreas Persidis. Drug repositioning has been attracting the interest of pharmaceutical and biotech companies for two reasons: commercial and scientific. On … Read More
Biovista Inc. announces positive efficacy results in a pre-clinical trial of BVA-101 for Multiple Sclerosis
CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ — Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in … Read More